https://publications.ersnet.org/content/erj/early/2026/01/29/1399300302574-2025
Enviado desde mi iPhone
PARTICIPA
martes, 17 de marzo de 2026
La convergencia digital: donde la atención centrada en el paciente se encuentra con el consumidor sanitario moderno - Observatori La gestió importa
Prevalence of symptomatic osteoarthritis in Spain: EPISER2016 study* - ScienceDirect
Sus números aunque algo antiguos siguen siendo aplastantes.
https://www.sciencedirect.com/science/article/abs/pii/S2173574320301398
Enviado desde mi iPhone
https://www.sciencedirect.com/science/article/abs/pii/S2173574320301398
Enviado desde mi iPhone
martes, 10 de marzo de 2026
LA VACUNA DE ESTE AÑO Y LA POCA RESPUESTA INMUNE
Como ya imaginabamos por la experiencia y por los datos que ya comentamos en otro post
la respuesta a la vacuna para la cepa de este año fue baja.
En la discusión:
These data suggest that baseline antibody titers to 2 H3N2 subclade K variants were lower than to other H1N1 and H3N2 strains and that antibody responses following vaccination were also significantly less robust to the H3N2 subclade K variants. Hemagglutination inhibition titers of 1:40 or greater are generally expected to be protective, with a 50% reduction in risk of clinically significant infection. These data indicate that the H3N2 subclade K strain partially evades both prior H3N2 immunity and the current inactivated influenza vaccine. Nevertheless, the modest boost of antibody titers following immunization suggests that the vaccine will still provide some benefit against H3N2 subclade K. However, the lower antibody titers to H3N2 subclade K compared with other recent influenza strains, both before and after vaccination, have important implications for the likely continued spread of this new influenza strain and for selection of future vaccine strains. The limitations of this study are its limited size and the fact that influenza antibody titers rather than clinical disease end points are reported.
Suscribirse a:
Comentarios (Atom)